The United States Food and Drug Administration (FDA) is responsible for ensuring the safety of genetically engineered animals, including fish, before they are allowed into the market for human consumption. In 2015, the FDA granted approval for the marketing and sale of the AquAdvantage salmon, concluding that the fish was safe for human consumption and did not pose any significant environmental risks.
According to the FDA, the AquAdvantage salmon is produced using a specific genetic modification technique, known as growth hormone transgenesis. This technique involves introducing a gene from the Chinook salmon into the genome of the Atlantic salmon. The Chinook salmon gene encodes a growth hormone that regulates the fish's growth rate. As a result, AquAdvantage salmon can grow faster and reach market size in less time compared to conventional Atlantic salmon.
As with any new food product, the introduction of genetically engineered fish has sparked discussions and debates about safety, environmental impact, and ethical considerations. While some individuals and organizations have raised concerns about potential risks associated with genetically modified organisms, the FDA and other regulatory bodies have evaluated the available data and concluded that AquAdvantage salmon meets all safety standards for human consumption.
It is important to note that the term "Frankenfish" often carries negative connotations and implies a sense of artificiality or unnaturalness. However, regulatory agencies such as the FDA have evaluated the safety and potential risks of AquAdvantage salmon and have determined that it does not pose any significant risks. Ultimately, the decision of whether or not to purchase and consume AquAdvantage salmon is a matter of personal choice and perspective.
